ClinicalTrials.gg
CompletedNCT06154447Updated Aug 10, 2026

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

A Phase 1 interventional study of VX-828 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 12 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
13th of 43
165 · median 100
Started
2023
with 1 other
Phase 1
5 of 43
2 open now
Registered
38th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 13th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 1, and was the 38th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Parts A-D:

  • Participants between the ages of 18 and 55 years
  • (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
  • A total body weight of more than (>) 50 kg
  • Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening
  • Cohort C2 only: Willing to provide a single DNA sample

Part E:

  • Participants 18 years or older
  • Confirmed diagnosis of CF as determined by the investigator
  • A total body weight of more than or equal to (>=) 35 kg
  • Participants must be heterozygous for F508del with a second CFTR allele carrying a minimal function mutation that is not responsive to ELX/TEZ/IVA therapy
  • Participants must have a (FEV1) of greater than or equal to (≥) 40% of predicted normal for age, sex, and height

Key Exclusion Criteria:

Parts A-D:

  • History of febrile illness or other acute illness within 14 days before the first dose of study drug
  • Any condition possibly affecting drug absorption

Part E:

  • An acute illness not related to CF (e.g., gastroenteritis) within 14 days before the first dose of study drug
  • History of solid organ or hematological transplantation
  • History of cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria will apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Part A: Single Ascending Dose (SAD)

    Participants will be randomized to receive a single dose of different dose levels of VX-828.

    Drug: VX-828

  • Placebo comparator
    Part A: Placebo

    Participants will be randomized to receive placebo matched to VX-828.

    Drug: Placebo

  • Experimental
    Part B: Multiple Ascending Dose (MAD)

    Participants will be randomized to receive multiple doses of different dose levels of VX-828. The dose levels will be determined based on the data from Part A.

    Drug: VX-828

  • Placebo comparator
    Part B: Placebo

    Participants will be randomized to receive placebo matched to VX-828.

    Drug: Placebo

  • Experimental
    Part C: Drug Drug Interaction

    Participants will receive a single dose of VX-828, followed by a washout period, Itraconazole administration, and concomitant administration of itraconazole and VX-828; or participants will receive Midazolam followed by VX-828/TEZ/D-IVA administration, and concomitant administration of VX-828/TEZ/D-IVA and Midazolam. Part C will be an open-label optional cohort.

    Drug: VX-828 · Drug: Itraconazole · Drug: Midazolam · Drug: Tezacaftor · Drug: Deutivacaftor

  • Experimental
    Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA

    Participants will be randomized to receive VX-828 in combination with TEZ/VX-118, TEZ/D-IVA, or D-IVA.

    Drug: VX-828 · Drug: Tezacaftor · Drug: VX-118 · Drug: Deutivacaftor

  • Placebo comparator
    Part D: Placebo

    Participants will be randomized to receive placebo matched to VX-828/TEZ/VX-118 or placebo matched to VX-828 in combination with TEZ/D-IVA or D-IVA

    Drug: Tezacaftor · Drug: Placebo · Drug: Deutivacaftor

  • Experimental
    Part E: VX-828 in Combination with D-IVA with or without TEZ in CF

    Participants with cystic fibrosis will receive VX-828 in combination with D-IVA with or without TEZ.

    Drug: Tezacaftor · Drug: Deutivacaftor · Drug: VX-828

Interventions

  • DrugVX-828

    Suspension for Oral Administration

  • DrugPlacebo

    Suspension for Oral Administration

  • Solution for Oral Administration

  • Syrup for Oral Administration

  • Tablets for Oral Administration

    Also known as: TEZ, VX-661

  • DrugVX-118

    Tablets for Oral Administration

  • DrugPlacebo

    Suspension and Tablets for Oral Administration

  • Tablets for Oral Administration

    Also known as: D-IVA, VX-561

  • DrugVX-828

    Tablets for Oral Administration

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 67)

  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)

  3. Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)

  4. Part E: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent Form (ICF) up to End of Study (Up to Day 111)

  5. Part C: Maximum Observed Concentration (Cmax) of VX-828 in Plasma in the Absence and Presence of Itraconazole

    Time frame: From Day 1 up to Day 71

  6. Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma in the Absence and Presence of Itraconazole

    Time frame: From Day 1 up to Day 71

  7. Part C: Maximum Observed Concentration (Cmax) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA

    Time frame: From Day 1 up to Day 30

  8. Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA

    Time frame: From Day 1 up to Day 30

Secondary outcomes

  1. Part A: Maximum Observed Concentration (Cmax) of VX-828 in Plasma

    Time frame: From Day 1 up to Day 67

  2. Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma

    Time frame: From Day 1 up to Day 67

  3. Part B: Maximum Observed Concentration (Cmax) of VX-828 at Day 28 in Plasma

    Time frame: From Day 1 up to Day 80

  4. Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-828 at Day 28 in Plasma

    Time frame: From Day 1 up to Day 80

  5. Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 82)

  6. Part D: Maximum Observed Concentration (Cmax) of VX-828, TEZ and D-IVA and their Metabolites at Day 28 in Plasma

    Time frame: Day 28

  7. Part D: Area Under the Concentration Versus Time Curve (AUC) of VX-828, TEZ and D-IVA and their Metabolites at Day 28 in Plasma

    Time frame: Day 28

  8. Part E: Maximum Observed Concentration (Cmax) of VX-828, TEZ, and D-IVA and their Metabolites in Plasma

    Time frame: Day 1 and Day 28

  9. Part E: Area Under the Concentration Versus Time Curve (AUC) of VX-828, TEZ, and D-IVA and their Metabolites in Plasma

    Time frame: Day 28

  10. Part E: Pre-dose Plasma Concentration (Ctrough) of VX-828, TEZ, D-IVA and its Metabolites

    Time frame: Pre-dose at Day 4, Day 8, Day 15, Day 22, Day 35, Day 49, Day 63, Day 80

  11. Part E: Absolute Change in Sweat Chloride

    Time frame: From Baseline and At Day 28

07

Study locations

12 sites
  • Joe DiMaggio Cycstic Fibrosis & Pulmonary Center
    Hollywood, Florida 33021, United States
  • AdventHealth Medical Group Pulmonology at Orlando Ridgewood
    Orlando, Florida 32803, United States
  • Altasciences Clinical Kansas
    Overland Park, Kansas 66212, United States
  • Kentucky Children's Hospital
    Lexington, Kentucky 40508, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Minnesota -Pulmonology
    Minneapolis, Minnesota 55455, United States
  • Billings Clinic, Pediatric Pulmonary Dept.
    Billings, Montana 59101, United States
  • New York Medical College
    Hawthorne, New York 10532, United States
  • ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC
    Toledo, Ohio 43606, United States
  • Cook Children's Pulmonology
    Fort Worth, Texas 76104, United States
  • University of Utah Hospital - Pulmonology
    Salt Lake City, Utah 84132, United States
  • Vermont Lung Center
    Colchester, Vermont 05446, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jul 2026, 30 months.

Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 30 months is above that.

Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
Dec 4, 2023
StartActual
Dec 12, 2023
Primary completionActual
Jul 10, 2026
CompletionActual
Jul 10, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06154447
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Dec 12, 2023
Primary completion
Jul 10, 2026
Completion
Jul 10, 2026
Last update
Aug 10, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion